Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03713424

An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction

This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Entry criteria:

Inclusion criteria

all subjects:

  • Age 18-65 years
  • English fluency
  • Functional vision (with corrective lenses as needed) to complete assigned assessments and tasks
  • Smoke > 10 cigarettes/day for a minimum of 2 yrs. and have an expired carbon monoxide (CO) concentration of ≥ 10 ppm (to confirm inhalation at screening and scanning)
  • If female, provide a negative urine pregnancy test.
  • Agrees to refrain from all other tobacco (i.e., dip/chew, cigars, cigarillos) and/or nicotine products (i.e., e-cigs, patches, gum/lozenges, inhalers/sprays) for the duration of study participation

Exclusion criteria

all subjects:

  • Sensitivity or allergy to clavulanic acid/antibiotics
  • Past head injury or primary neurological disorder associated with MRI abnormalities, including dementia, MCI, brain tumors, epilepsy, Parkinson's disease, or demyelinating diseases
  • Any physical or intellectual disability affecting completion of assessments
  • Any contraindication to MRI
  • Use of antidepressants medications with smoking cessation efficacy
  • Presence of an untreated illness or serious medical condition
  • Current or past psychosis
  • Electroconvulsive therapy in last 6 months
  • Positive pregnancy test (Urine pregnancy testing at screening and prior to fMRI scan) or currently breast feeding or BAC greater than 0.0
  • Use of carbamazepine or nitroglycerin (or any other medication deemed to be hazardous if taken with CLAV) within 14 days of study participation
  • Abnormal liver function determined by Complete Metabolic Panel - liver enzymes outside normal ranges of AST (SGOT) 5-40 unites/L and ALT( SGPT) 7-56units/L
  • Abnormal renal function determined by Complete Metabolic Panel - outside normal ranges of BUN 6-24 mg /dl and Creatinine level 0.6 -1.2 mg /dl male, 0.5-1.1mg /dl female
  • Any other condition or concern that in the investigator's opinion would impact participant safety, compliance with study instructions, or potentially confound the interpretation of the study results

Treatment and study plan

Clavulanic Acid

Drug

Beta lactamase inhibitor for smoking cessation

Placebo oral capsule

Drug

placebo

Primary outcomes

  1. Cigarette Smoking

    Time frame: 5 days

    Biochemical smoking assessment (breath carbon monoxide) at each study visit.

  2. Self Reported Side Effects

    Time frame: 5 Days

    Number of reported side effects

Secondary outcomes

  1. Magnitude of change in BOLD fMRI brain response to smoking related images

    Time frame: 4 days

    Measure the effects of Clavulanic Acid on fMRI BOLD response to images (change from baseline to end of study) while participants undergo functional magnetic resonance imaging

  2. Magnitude of change in resting-stated fMRI brain connectivity

    Time frame: 4 days

    Measure the effects of Clavulanic Acid on resting-state functional connectivity (change from baseline to end of study) while participants undergo functional magnetic resonance imaging.

Study contacts

Contact information is provided by the study sponsor or research team.

Brett E Froeliger, PhD

CONTACT

[email protected]

573-882-4785

Madhura Athreya, MS

CONTACT

[email protected]

573-882-2977

Sponsors and collaborators

Lead sponsor

University of Missouri-Columbia

Other

Registry information

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Oct 19, 2018
Registry last updated
Oct 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.